Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

NCT05375435 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Dermatomyositis, Adult Type
Interstitial Lung Disease

Interventions

DRUG: triple therapy
DRUG: dual-therapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University